Dr. Tetsuro Yamamoto, Director of the Research Center of EPS Innovative Medicine Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Representative Director: Satoshi Okoso), together with Professor Keiichi Tsukinoki of Kanagawa Dental University and Professor Emeritus Hideyo Yamaguchi of Teikyo University, reported the results suggesting that secretory immunoglobulin A is associated with lower incidence of COVID-1 9 in Japan.
【Key points of this research】
・Noting that as of November 2020, the incidence of COVID-19 is extremely low in Japan despite the fact that vaccination rates are lower than in other countries. ・Among immunoglobulins, we hypothesized that infection with SARS-CoV-2 is inhibited especially by secretory immunoglobulin A (sIgA) secreted from mucous membranes. ・Saliva samples were collected and examined from all the 180 healthy participants from Japan who had not been exposed to SARS‐CoV‐2. 95 people (or 52.78% of the total) of the individuals were positive for saliva IgA antibodies. It was observed among the study that IgA antibody is associated with a low incidence of covid-19.
【Outline of Paper Publication】
The results of this research are published in Microbiology and Immunology published in August 2022.
|Title||Prevalence of saliva immunoglobulin A antibodies reactive with severe acute respiratory syndrome coronavirus 2 among Japanese people unexposed to the virus.|
|Authors||Tsukinoki K(1), Yamamoto T(2), Saito J(3), Sakaguchi W(1), Iguchi K(4), Inoue Y(5), et al.|
|Affiliation||(1)Kanagawa Dental University Graduate School of Environmental Pathology (2)EPS Holdings Co., Ltd./ EPS Innovative Medicine Co., Ltd. (3)Medical Station Clinic (4)Department of Orthodontics, Kanagawa Dental University (5)Department of Pediatric Dentistry, Kanagawa Dental University|
|EPS.Innovative Medicine Co., Ltd.
Research Center Kazuki Tajima
E-mail : email@example.com